A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53
Authors:
- Anne VäisänenAVAnne Väisänen
- Paula KuvajaPKPaula Kuvaja
- Matti KallioinenMKMatti Kallioinen
- Taina Turpeenniemi-HujanenTTTaina Turpeenniemi-Hujanen
- 1 August 2011
- journal article
- Published by Elsevier in Human Pathology
- Vol. 42 (8) , 1103-1111
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2009
- Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanomaHuman Pathology, 2008
- Matrix metalloproteinases and tumor metastasisCancer and Metastasis Reviews, 2006
- Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancersBiochimie, 2005
- Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker inbladder cancerUrology, 2003
- Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinomaBritish Journal of Cancer, 2003
- Metalloproteinase inhibitors: biological actions and therapeutic opportunitiesJournal of Cell Science, 2002
- Complex roles of tissue inhibitors of metalloproteinases in cancerOncogene, 2002
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanomaThe Journal of Pathology, 1998